A small biotech is pushing a gene therapy for Rett syndrome toward a key trial stage, and early patient results look encouraging. If regulators keep signaling a fast path and the treatment keeps proving safe and helpful, approval could come sooner—but delays, cash burn, and tough manufacturing could still derail it.Read more
Catalysts About Taysha Gene Therapies Taysha Gene Therapies develops gene therapies for Rett syndrome, focusing on its TSHA-102 program. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About Taysha Gene Therapies Taysha Gene Therapies is a clinical stage biotechnology company developing AAV based gene therapies for monogenic central nervous system disorders, with TSHA-102 for Rett syndrome as its lead program. What are the underlying business or industry changes driving this perspective?Read more
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
